11:44 AM EDT, 05/14/2024 (MT Newswires) -- Kura Oncology ( KURA ) said Tuesday it completed the enrollment of 85 patients in the phase 2 segment of the clinical trial for potential leukemia drug Ziftomenib.

The study evaluates Ziftomenib's effectiveness, safety and tolerance in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia, focusing on achieving a complete response, the company said.

Kura Oncology ( KURA ) plans to release topline data from the trial in early 2025.

Shares of Kura Oncology ( KURA ) rose.1.4% in recent Tuesday trading.

Price: 20.91, Change: +0.30, Percent Change: +1.43